l General Information |
Product Name | VE-822 |
General description | VE-822 is an ATR inhibitor. |
Synonym | 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine; VX970, Berzosertib |
Purity | ≥98.0%(HPLC) | CAS Number | 1232416-25-9 |
Formula | C24H25N5O3S | Molecular Weight | 463.55 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | solid |
Solubility(25℃) | DMSO | ≥35mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells. |
Application | Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This
product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
